ERBB2 and neoplasm: Notably, lapatinib enhanced the sensitivity of four tumor organoids derived from different BRCA cancer patients (2 Luminal A, 1 Luminal B1, and 1 HER2-enriched) to Lipo-Dox (Figure 6C, 6D, and 6E; Supplementary Figure S9B and S9C).